Alzheimer’s

First Opinion Carolyn Clevenger

Outdated Medicare rules prevent some dementia patients from getting the medications they need

Biotech Matthew Herper

STAT Plus: Getting Alzheimer’s treatment to those who need it poses particular challenges

STAT Events Megan Molteni

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

The Readout Elaine Chen

STAT Plus: Vertex starts gene therapy Casgevy in five patients 

Health Jonathan Wosen

STAT Plus: Alzheimer’s risk gene APOE4 may cause a distinct form of the disease, study suggests

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

Biotech Adam Feuerstein

STAT Plus: Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede

Health Care Inc. Bob Herman

Medicare expects a big spike in spending on Leqembi

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech

Exclusive Bob Herman and Rachel Cohrs Zhang

STAT Plus: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025

First Opinion Katherine O'Malley

Primary care physicians should be at the heart of treating Alzheimer’s

The Readout Meghana Keshavan

STAT Plus: Preventing the weaponization of AI-designed proteins

Biotech Andrew Joseph

STAT Plus: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug

Biotech Adam Feuerstein

STAT Plus: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Biogen Alzheimer’s drug launch off to slow start

Letters to the editor Torie Bosch

What STAT readers think about Aduhelm, CTE and the Super Bowl, and more

First Opinion Jason Karlawish

STAT Plus: Aduhelm was a mess — and it could happen again

The Readout Meghana Keshavan

STAT Plus: What makes a drug a blockbuster — or a cautionary tale?

Biotech Damian Garde

STAT Plus: Years after a polarizing approval, Biogen walks away from Aduhelm

In the Lab Andrew Joseph

Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure

Health tech Mario Aguilar

STAT Plus: Cognito raises $35 million for Alzheimer’s treatment device, touts benefits compared to drugs

Letters to the editor Torie Bosch

STAT readers on patient advocacy, the utility of diagnostic tests, and more

First Opinion Jon Hu

Alzheimer’s drug approvals show we need a reevaluation of patient advocacy

The Readout Meghana Keshavan

STAT Plus: Today’s biotech news roundup, in under 800 words

The Readout Damian Garde

STAT Plus: Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead

Adam's Take Adam Feuerstein

STAT Plus: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

ESMO highlights, Roivant’s big deal, & biotech VC on the rise

The Readout Damian Garde

STAT Plus: Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Biotech Adam Feuerstein

STAT Plus: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show